Year
|
Milestone |
2009
|
$ 800K Convertible Note Financing
Selected as finalist for “Best Early-Stage Vaccine Biotech” for 2009 World Vaccine Congress
Successful pre-IND Meeting for ApoVax104-HPV vaccine held on May 7th 2009
|
 |
2008
|
Selected for NIH Commercialization Assistance Program (CAP)
Completed License Agreement for ApoFasL technology with large pharmaceutical company
Completed License Agreement for ApoVax104 technology with large pharmaceutical company
$ 600K Kentucky DCI Matching Fund Awards
$ 822K NIH Phase I SBIR, Tuberculosis Vaccine
$ 1.64MM NIH Phase II SBIR, Cervical Cancer Vaccine
$ 635K Convertible Note Financing
|
|
|
|
|
2007
|
$ 200K Kentucky DCI Matching Fund Awards
$ 328K NIH Phase I STTR, Universal Tumor Vaccine
$ 422K NIH Phase I SBIR, Type 1 Diabetes
$ 300K NIH Phase I SBIR, Cervical Cancer Vaccine
|
|
|
|
|
2006
|
ApoVax104 and Related Patents Filed
$ 500K Kentucky DCI Forgivable Loan
$ 290K Convertible Note Financing
|
|
|
|
|
2005
|
$ 769K NIH Phase I SBIR grant
$ 1.1MM Series A Financing
|
|
|
|
|
2004
|
$ 100K NIH Phase I STTR grant
|
|
|
|
|
2003
|
$ 255K Common Equity Financing
|
|
|
|
|
2002
|
$ 100K NIH Phase I STTR grant
$ 400K Jewish Hospital and St. Mary's Hospital Seed grant
|
|
|
|
|
2001
|
Company Founded
|
